Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | YWHAH | Q04917 | 4/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4261606 | 0.91 | S1PR3 (0.52) | POLBS1PR3FOLH1PPARGF2 | |
| SCHEMBL8179717 | 0.91 | PTGER4 (0.49) | POLBS1PR3FOLH1PPARGTHRA | |
| SCHEMBL8167328 | 0.87 | MEN1 (0.52) | POLBS1PR3FOLH1PPARGTHRA | |
| SCHEMBL8165177 | 0.85 | PPARG (0.47) | S1PR3FOLH1PPARGF2F10 | |
| SCHEMBL8175838 | 0.85 | PTGER4 (0.47) | S1PR3FOLH1PPARGTHRATHRB | |
| SCHEMBL8180895 | 0.84 | PPARG (0.52) | S1PR3FOLH1PPARGF2F10 | |
| SCHEMBL13952371 | 0.84 | PTGER4 (0.48) | S1PR3FOLH1PPARGF2F10 | |
| SCHEMBL13931389 | 0.83 | PLA2G2A (0.49) | S1PR3FOLH1PPARGF2F10 | |
| SCHEMBL8175849 | 0.82 | PTGER4 (0.49) | S1PR3FOLH1PPARGYWHAHTHRA | |
| SCHEMBL8180889 | 0.82 | S1PR3 (0.47) | S1PR3FOLH1PPARGTHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008100867-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | POLB 330/4885S1PR3 3354/4885FOLH1 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.